top
Please input keywords
Product Pipeline
Develop antibody drugs to meet patients' needs
Biocytogen is committed to developing innovative antibody drugs that meet the needs of patients, focusing on oncology, autoimmune, inflammatory, metabolic and and other diseases. Taking full advantage of its unique advantage in innovative drug development the company now has more than 10 R & D pipelines including monoclonal antibodies, bispecific antibodies, ADC drugs and so on. With the support of a strong clinical development team and abundant clinical resources, the company will push forward the product pipeline at full speed to accelerate the clinical trial process.
Therapeutic Area
Products
Target
Partner
Molecular Format
Indication
Status
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Oncology
YH003
CD40
Monoclonal antibody
Solid Tumor
More
YH001
CTLA-4
Monoclonal Antibody
Solid Tumor
More
YH002
OX40
Monoclonal Antibody
Solid Tumor
More
YH004
4-1BB
Monoclonal antibody
More
YH005-ADC
Claudin18.2- ADC
Remegen
ADC
More
YH008
PD-1/CD40
Bispecific antibody
More
YH006
CTLA-4/OX40
Bi-specific antibody
More
YH010
PD-L1/IL12
Bi-specific antibody
More
YH011
PD-L1/cytokine
GeneQuantum
More
YH012
Bispecific ADC
More
YH013
Bispecific ADC
More
Infectious Diseases
YH009
RSV
Monoclonal antibody
More
Oncology
YH003
More
Target:
CD40
Partner:
Molecular Format:
Monoclonal antibody
Indication:
Solid Tumor
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH001
More
Target:
CTLA-4
Partner:
Molecular Format:
Monoclonal Antibody
Indication:
Solid Tumor
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH002
More
Target:
OX40
Partner:
Molecular Format:
Monoclonal Antibody
Indication:
Solid Tumor
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH004
More
Target:
4-1BB
Partner:
Molecular Format:
Monoclonal antibody
Indication:
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH005-ADC
More
Target:
Claudin18.2- ADC
Partner:
Remegen
Molecular Format:
ADC
Indication:
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH008
More
Target:
PD-1/CD40
Partner:
Molecular Format:
Bispecific antibody
Indication:
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH006
More
Target:
CTLA-4/OX40
Partner:
Molecular Format:
Bi-specific antibody
Indication:
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH010
More
Target:
PD-L1/IL12
Partner:
Molecular Format:
Bi-specific antibody
Indication:
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH011
More
Target:
PD-L1/cytokine
Partner:
GeneQuantum
Molecular Format:
Indication:
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH012
More
Target:
Partner:
Molecular Format:
Bispecific ADC
Indication:
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH013
More
Target:
Partner:
Molecular Format:
Bispecific ADC
Indication:
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Infectious Diseases
YH009
More
Target:
RSV
Partner:
Molecular Format:
Monoclonal antibody
Indication:
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Biocytogen has reached licensing agreements on its proprietary human antibody mice based discovery platforms and strategic antibody drug co-development partnerships with many pharmaceutical companies around the world. Click the button below to learn more about the collaboration models.For pipeline related collaboration, please contact: bd@eucure.com
Cooperation theme